Sam Waksal
Sam Waksal
Samuel D. "Sam" Waksal, Ph.D.,is the founder and former CEO of the biopharmaceutical company ImClone Systems. He is also the founder and Chief of Innovation, Science and Strategy of Kadmon Pharmaceuticals which was financed with private capital and commenced operations in New York City in 2010. At ImClone, Waksal led the company to develop the landmark cancer drug Erbitux. During the course of its review process with Food and Drug AdministrationWaksal became involved in an insider trading scandal revolving around...